Therapeutic Focus

Alzheimer’s Disease

It was in 2015 that an article appeared in Nature Medicine that suggested in the animal model of AD, use of Salsalate had a markedly beneficial outcome in terms of the behavior, brain size and pathological markers in such animals. The dose they used in their mouse model of AD, was the equivalent of 2250 mg per day of Salsalate for humans.

Dr. Adam Boxer in San Francisco has secured funding and it now testing this drug in mild to moderate AD patients.

If it shows benefit then it might be the next FDA approved drug for AD.